



BMS-820132 | GK

oral GK partial activator
Ph. I candidate for diabetes
from HTS of BMS collection and SBDD
J. Med. Chem.
Bristol Myers Squibb




Compound 14f | ChemR23

oral ChemR23 inhibitor
preclinical, immunology
from HTS, scaffold hopping and opt.
Bioorg. Med. Chem.
Kyowa Kirin




GCC5694A | SGLT2

oral SGLT2 inhibitor
clinical candidate for diabetes
from literature SGLT2 inhibitor
Bioorganic Med. Chem. Lett.
GC Pharma (Green Cross)




LY3154885 | D1

oral D1 modulator
Ph. I candidate for neurological disorders
opt. against DDI w/ hepatocyte Cl assay
J. Med. Chem.
Eli Lilly and Company




Danavorexton | OX2

injectable OX2 agonist
Ph. I candidate for narcolepsy
from HTS and optimization
ACS Med. Chem. Lett.
Takeda




AZ13824374 | ATAD2

in vitro ATAD2 inhibitor
preclinical, oncology
from 1.8 million compound HTS and opt.
J. Med. Chem.
AstraZeneca




ASP5878 | FGFR

oral FGFR inhibitor
Ph. I candidate for solid tumors
opt. from previously disclosed lead
Bioorg. Med. Chem.
Astellas Pharma Inc.




AZD7648 | DNA-PK

oral DNA-PK inhibitor
Ph. I/II candidate for advanced tumors
from screening for selectivity vs. PI3Ka
Mol. Cancer Ther.
AstraZeneca



T-690 | GCS

oral GCS inhibitor
preclinical, neurodegeneration
scaffold hop from prev. reported GCS inhibitor
J. Med. Chem.
Takeda



MAP855 | MEK1/2

oral MEK1/2 inhibitor
preclinical, oncology
from HTS and SBDD
J. Med. Chem.
Novartis Institutes for BioMedical Research